분자 세포유전 시장 : 제품별, 기술별, 용도별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2021-2031년)

The global molecular cytogenetics market was valued at $2,233.5 million in 2021, and is projected to reach $5,146.55 million by 2031, registering a CAGR of 8.7%.

Molecular cytogenetics includes the chromosome biology and the use of molecular cytogenetic methods in biology and medicine. These include the structural and functional establishment of the chromosome and nucleus, genome variation, expression, and evolution, chromosome abnormalities, and genomic variations in tumor genetics and medical genetics. The testing includes identifying a specific gene or gene locus (molecular) with direct visualization of the cells and chromosomes under a fluorescence microscope and is far from being outdated and is actively involved in up-to-date diagnostics and research.

According to National Center for Biotechnology Information (NCBI), an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. This prevalence of cancer diseases among all age groups owing to changes (mutations) to the DNA within cells, will lead to the increase in the demand for diagnostic techniques of molecular cytogenetics.

Furthermore, the growth of the molecular cytogenetics market is anticipated to be facilitated by the introduction of numerous cutting-edge diagnostic technologies by the biotechnology companies, an increase in demand for accurate diagnosis of serious cancer diseases, and the availability of interventional pathologist with the necessary training in developed economies.

In addition, advancements in molecular cytogenetics, increase in incidence of genetic disorders & cancer and rise in awareness & acceptance of personalized medicines, are some of the factors that are boosting the market growth. The development of the techniques including interphase fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), multicolor karyotyping, telomere FISH, primed in situ labelling (PRINS), and telomere FISH, have caused the expansion of the market. However, the market is expected to be significantly constrained in the near future by factors such as high cost associated with the procedure.

In addition, the use of molecular pathology in disease diagnosis, disease prevention, and treatment is now possible using the molecular cytogenetics. For instance, the development of the BioPrime Total Genomic Labeling System by the Thermo Fisher Scientific, which is a complete genomic DNA labeling system designed for use in array comparative genomic hybridization applications (aCGH) that allows for better call rates with precious samples.

The molecular cytogenetics market is segmented on the basis of product, technique, application, end user and region. By product, it is divided into instruments, consumables, and software & services. On the basis of technique, the market is segmented into comparative genomic hybridization, fluorescence in situ hybridization and others. Further, the comparative genomic hybridization segment is divided into array-based comparative genomic hybridization and standard comparative genomic hybridization. By application, the market is segmented into genetic disorders, cancer, personalized medicine and others. According to the end user, the market is segmented into clinical & research laboratories, pharmaceutical & biotechnology companies and others (academic research institutes, contract research organization [CRO]). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in this report include Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging, Cyto Test Inc., Danaher Corporation (Cephied), Empire Genomics, LLC., Genial Genetic Solutions Ltd., Illumina, Inc., Perkinelmer, Inc., Sema4 Holdings Corp., Sysmex Corporation (Oxford Gene Technology) and Thermo Fisher Scientific Inc. and among others.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the molecular cytogenetics market analysis from 2021 to 2031 to identify the prevailing molecular cytogenetics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the molecular cytogenetics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global molecular cytogenetics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

• Instruments
• Consumables
• Software and Services

By Technique

• Comparative Genomic Hybridization
  • Type
  • Array-Based Comparative Genomic Hybridization
  • Standard Comparative Genomic Hybridization
• Fluorescence in Situ Hybridization
• Others

By Application

• Genetic Disorders 
• Cancer 
• Personalized Medicines
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Others
• Clinical and Research Laboratories

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Applied Spectral Imaging
  • Cyto Test Inc.
  • Danaher Corporation (Cephied)
  • Empire Genomics, LLC.
  • Genial Genetic Solutions Ltd.
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • Sema4 Holdings Corp.
  • Sysmex Corporation (Oxford Gene Technology)
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market
• 3.7.Patent Landscape

CHAPTER 4: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Instruments
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Consumables
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Software and Services
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country

CHAPTER 5: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Comparative Genomic Hybridization
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
  • 5.2.4 Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
    • 5.2.4.1 Array-Based Comparative Genomic Hybridization Market size and forecast, by region
    • 5.2.4.2 Standard Comparative Genomic Hybridization Market size and forecast, by region
• 5.3 Fluorescence in Situ Hybridization
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Others
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country

CHAPTER 6: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Genetic Disorders 
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Cancer 
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
• 6.4 Personalized Medicines
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country
• 6.5 Others
  • 6.5.1 Key market trends, growth factors and opportunities
  • 6.5.2 Market size and forecast, by region
  • 6.5.3 Market analysis by country

CHAPTER 7: MOLECULAR CYTOGENETICS MARKET, BY END USER

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 Clinical and Research Laboratories
  • 7.2.1 Key market trends, growth factors and opportunities
  • 7.2.2 Market size and forecast, by region
  • 7.2.3 Market analysis by country
• 7.3 Pharmaceutical and Biotechnology Companies
  • 7.3.1 Key market trends, growth factors and opportunities
  • 7.3.2 Market size and forecast, by region
  • 7.3.3 Market analysis by country
• 7.4 Others
  • 7.4.1 Key market trends, growth factors and opportunities
  • 7.4.2 Market size and forecast, by region
  • 7.4.3 Market analysis by country

CHAPTER 8: MOLECULAR CYTOGENETICS MARKET, BY REGION

• 8.1 Overview
  • 8.1.1 Market size and forecast
• 8.2 North America
  • 8.2.1 Key trends and opportunities
  • 8.2.2 North America Market size and forecast, by Product
  • 8.2.3 North America Market size and forecast, by Technique
    • 8.2.3.1 North America Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
  • 8.2.4 North America Market size and forecast, by Application
  • 8.2.5 North America Market size and forecast, by End User
  • 8.2.6 North America Market size and forecast, by country
    • 8.2.6.1 U.S.
    • 8.2.6.1.1 Market size and forecast, by Product
    • 8.2.6.1.2 Market size and forecast, by Technique
    • 8.2.6.1.3 Market size and forecast, by Application
    • 8.2.6.1.4 Market size and forecast, by End User
    • 8.2.6.2 Canada
    • 8.2.6.2.1 Market size and forecast, by Product
    • 8.2.6.2.2 Market size and forecast, by Technique
    • 8.2.6.2.3 Market size and forecast, by Application
    • 8.2.6.2.4 Market size and forecast, by End User
    • 8.2.6.3 Mexico
    • 8.2.6.3.1 Market size and forecast, by Product
    • 8.2.6.3.2 Market size and forecast, by Technique
    • 8.2.6.3.3 Market size and forecast, by Application
    • 8.2.6.3.4 Market size and forecast, by End User
• 8.3 Europe
  • 8.3.1 Key trends and opportunities
  • 8.3.2 Europe Market size and forecast, by Product
  • 8.3.3 Europe Market size and forecast, by Technique
    • 8.3.3.1 Europe Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
  • 8.3.4 Europe Market size and forecast, by Application
  • 8.3.5 Europe Market size and forecast, by End User
  • 8.3.6 Europe Market size and forecast, by country
    • 8.3.6.1 Germany
    • 8.3.6.1.1 Market size and forecast, by Product
    • 8.3.6.1.2 Market size and forecast, by Technique
    • 8.3.6.1.3 Market size and forecast, by Application
    • 8.3.6.1.4 Market size and forecast, by End User
    • 8.3.6.2 France
    • 8.3.6.2.1 Market size and forecast, by Product
    • 8.3.6.2.2 Market size and forecast, by Technique
    • 8.3.6.2.3 Market size and forecast, by Application
    • 8.3.6.2.4 Market size and forecast, by End User
    • 8.3.6.3 UK
    • 8.3.6.3.1 Market size and forecast, by Product
    • 8.3.6.3.2 Market size and forecast, by Technique
    • 8.3.6.3.3 Market size and forecast, by Application
    • 8.3.6.3.4 Market size and forecast, by End User
    • 8.3.6.4 Italy
    • 8.3.6.4.1 Market size and forecast, by Product
    • 8.3.6.4.2 Market size and forecast, by Technique
    • 8.3.6.4.3 Market size and forecast, by Application
    • 8.3.6.4.4 Market size and forecast, by End User
    • 8.3.6.5 Spain
    • 8.3.6.5.1 Market size and forecast, by Product
    • 8.3.6.5.2 Market size and forecast, by Technique
    • 8.3.6.5.3 Market size and forecast, by Application
    • 8.3.6.5.4 Market size and forecast, by End User
    • 8.3.6.6 Rest of Europe
    • 8.3.6.6.1 Market size and forecast, by Product
    • 8.3.6.6.2 Market size and forecast, by Technique
    • 8.3.6.6.3 Market size and forecast, by Application
    • 8.3.6.6.4 Market size and forecast, by End User
• 8.4 Asia-Pacific
  • 8.4.1 Key trends and opportunities
  • 8.4.2 Asia-Pacific Market size and forecast, by Product
  • 8.4.3 Asia-Pacific Market size and forecast, by Technique
    • 8.4.3.1 Asia-Pacific Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
  • 8.4.4 Asia-Pacific Market size and forecast, by Application
  • 8.4.5 Asia-Pacific Market size and forecast, by End User
  • 8.4.6 Asia-Pacific Market size and forecast, by country
    • 8.4.6.1 Japan
    • 8.4.6.1.1 Market size and forecast, by Product
    • 8.4.6.1.2 Market size and forecast, by Technique
    • 8.4.6.1.3 Market size and forecast, by Application
    • 8.4.6.1.4 Market size and forecast, by End User
    • 8.4.6.2 China
    • 8.4.6.2.1 Market size and forecast, by Product
    • 8.4.6.2.2 Market size and forecast, by Technique
    • 8.4.6.2.3 Market size and forecast, by Application
    • 8.4.6.2.4 Market size and forecast, by End User
    • 8.4.6.3 Australia
    • 8.4.6.3.1 Market size and forecast, by Product
    • 8.4.6.3.2 Market size and forecast, by Technique
    • 8.4.6.3.3 Market size and forecast, by Application
    • 8.4.6.3.4 Market size and forecast, by End User
    • 8.4.6.4 India
    • 8.4.6.4.1 Market size and forecast, by Product
    • 8.4.6.4.2 Market size and forecast, by Technique
    • 8.4.6.4.3 Market size and forecast, by Application
    • 8.4.6.4.4 Market size and forecast, by End User
    • 8.4.6.5 South Korea
    • 8.4.6.5.1 Market size and forecast, by Product
    • 8.4.6.5.2 Market size and forecast, by Technique
    • 8.4.6.5.3 Market size and forecast, by Application
    • 8.4.6.5.4 Market size and forecast, by End User
    • 8.4.6.6 Rest of Asia-Pacific
    • 8.4.6.6.1 Market size and forecast, by Product
    • 8.4.6.6.2 Market size and forecast, by Technique
    • 8.4.6.6.3 Market size and forecast, by Application
    • 8.4.6.6.4 Market size and forecast, by End User
• 8.5 LAMEA
  • 8.5.1 Key trends and opportunities
  • 8.5.2 LAMEA Market size and forecast, by Product
  • 8.5.3 LAMEA Market size and forecast, by Technique
    • 8.5.3.1 LAMEA Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
  • 8.5.4 LAMEA Market size and forecast, by Application
  • 8.5.5 LAMEA Market size and forecast, by End User
  • 8.5.6 LAMEA Market size and forecast, by country
    • 8.5.6.1 Brazil
    • 8.5.6.1.1 Market size and forecast, by Product
    • 8.5.6.1.2 Market size and forecast, by Technique
    • 8.5.6.1.3 Market size and forecast, by Application
    • 8.5.6.1.4 Market size and forecast, by End User
    • 8.5.6.2 Saudi Arabia
    • 8.5.6.2.1 Market size and forecast, by Product
    • 8.5.6.2.2 Market size and forecast, by Technique
    • 8.5.6.2.3 Market size and forecast, by Application
    • 8.5.6.2.4 Market size and forecast, by End User
    • 8.5.6.3 South Africa
    • 8.5.6.3.1 Market size and forecast, by Product
    • 8.5.6.3.2 Market size and forecast, by Technique
    • 8.5.6.3.3 Market size and forecast, by Application
    • 8.5.6.3.4 Market size and forecast, by End User
    • 8.5.6.4 Rest of LAMEA
    • 8.5.6.4.1 Market size and forecast, by Product
    • 8.5.6.4.2 Market size and forecast, by Technique
    • 8.5.6.4.3 Market size and forecast, by Application
    • 8.5.6.4.4 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

• 10.1 Abbott Laboratories
  • 10.1.1 Company overview
  • 10.1.2 Company snapshot
  • 10.1.3 Operating business segments
  • 10.1.4 Product portfolio
  • 10.1.5 Business performance
  • 10.1.6 Key strategic moves and developments
• 10.2 Agilent Technologies Inc.
  • 10.2.1 Company overview
  • 10.2.2 Company snapshot
  • 10.2.3 Operating business segments
  • 10.2.4 Product portfolio
  • 10.2.5 Business performance
  • 10.2.6 Key strategic moves and developments
• 10.3 Applied Spectral Imaging
  • 10.3.1 Company overview
  • 10.3.2 Company snapshot
  • 10.3.3 Operating business segments
  • 10.3.4 Product portfolio
  • 10.3.5 Business performance
  • 10.3.6 Key strategic moves and developments
• 10.4 Cyto Test Inc.
  • 10.4.1 Company overview
  • 10.4.2 Company snapshot
  • 10.4.3 Operating business segments
  • 10.4.4 Product portfolio
  • 10.4.5 Business performance
  • 10.4.6 Key strategic moves and developments
• 10.5 Danaher Corporation (Cephied)
  • 10.5.1 Company overview
  • 10.5.2 Company snapshot
  • 10.5.3 Operating business segments
  • 10.5.4 Product portfolio
  • 10.5.5 Business performance
  • 10.5.6 Key strategic moves and developments
• 10.6 Empire Genomics, LLC.
  • 10.6.1 Company overview
  • 10.6.2 Company snapshot
  • 10.6.3 Operating business segments
  • 10.6.4 Product portfolio
  • 10.6.5 Business performance
  • 10.6.6 Key strategic moves and developments
• 10.7 Genial Genetic Solutions Ltd.
  • 10.7.1 Company overview
  • 10.7.2 Company snapshot
  • 10.7.3 Operating business segments
  • 10.7.4 Product portfolio
  • 10.7.5 Business performance
  • 10.7.6 Key strategic moves and developments
• 10.8 Illumina, Inc.
  • 10.8.1 Company overview
  • 10.8.2 Company snapshot
  • 10.8.3 Operating business segments
  • 10.8.4 Product portfolio
  • 10.8.5 Business performance
  • 10.8.6 Key strategic moves and developments
• 10.9 PerkinElmer, Inc.
  • 10.9.1 Company overview
  • 10.9.2 Company snapshot
  • 10.9.3 Operating business segments
  • 10.9.4 Product portfolio
  • 10.9.5 Business performance
  • 10.9.6 Key strategic moves and developments
• 10.10 Sema4 Holdings Corp.
  • 10.10.1 Company overview
  • 10.10.2 Company snapshot
  • 10.10.3 Operating business segments
  • 10.10.4 Product portfolio
  • 10.10.5 Business performance
  • 10.10.6 Key strategic moves and developments
• 10.11 Sysmex Corporation (Oxford Gene Technology)
  • 10.11.1 Company overview
  • 10.11.2 Company snapshot
  • 10.11.3 Operating business segments
  • 10.11.4 Product portfolio
  • 10.11.5 Business performance
  • 10.11.6 Key strategic moves and developments
• 10.12 Thermo Fisher Scientific Inc.
  • 10.12.1 Company overview
  • 10.12.2 Company snapshot
  • 10.12.3 Operating business segments
  • 10.12.4 Product portfolio
  • 10.12.5 Business performance
  • 10.12.6 Key strategic moves and developments